# Bioavailability of Empagliflozin/Metformin Fixed Dose Combinations (FDCs) in Healthy Chinese Volunteers

> **NCT02102932** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 96 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** 5 mg empagliflozin/850 mg metformin FDC
- **DRUG:** 12.5 mg empagliflozin
- **DRUG:** 12.5 mg empagliflozin
- **DRUG:** 850 mg metformin
- **DRUG:** 5 mg empagliflozin
- **DRUG:** 5 mg empagliflozin
- **DRUG:** 850 mg metformin
- **DRUG:** 12.5 mg empagliflozin/850 mg metformin FDC
- **DRUG:** 12.5 mg empagliflozin/500 mg metformin FDC
- **DRUG:** 5 mg empagliflozin/500 mg metformin FDC
- **DRUG:** 500 mg metformin
- **DRUG:** 500 mg metformin

## Key facts

- **NCT ID:** NCT02102932
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2015-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02102932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02102932, "Bioavailability of Empagliflozin/Metformin Fixed Dose Combinations (FDCs) in Healthy Chinese Volunteers". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02102932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*